Immunotherapy added to radiation therapy boosts survival in localized prostate cancer

MedicalXpress | 六月 02, 2026

Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy aglatimagene besadenovec (alglatimagene, CAN-2409) to standard radiation therapy improved disease-free survival for patients with intermediate- or high-risk localized prostate cancer. The study was led by researchers at the Johns Hopkins University School of Medicine, Johns Hopkins Kimmel Cancer Center, Department of Radiation Oncology and Molecular Radiation Sciences, and Brady Urological Institute. Findings from the study were published June 1 in The Lancet Oncology.